Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

699
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
699
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Therapies02:49

Cancer Therapies

8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide Images.

Cancer research·2026
Same author

Translational aspects of Desmoplastic small round cell tumor (DSRCT): An expert consensus paper from the OCTOPUS group.

Critical reviews in oncology/hematology·2026
Same author

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.

Cancer research communications·2026
Same author

Novel Synthetic Lethal Therapeutic Strategies in Precision Oncology.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study.

European journal of cancer (Oxford, England : 1990)·2026
Same author

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours.

European journal of cancer (Oxford, England : 1990)·2026

Related Experiment Video

Updated: Sep 29, 2025

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.5K

Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments.

Carine Ngo1,2, Sophie Postel-Vinay1,3

  • 1ATIP-Avenir Group, Inserm Unit U981, Gustave Roussy, 94800 Villejuif, France.

Biomedicines
|March 25, 2022
PubMed
Summary

SMARCB1-deficient cancers, though genomically simple, show immunogenicity. This review explores preclinical and clinical data suggesting immunotherapy, including checkpoint inhibitors, may be a viable treatment strategy for these tumors.

Keywords:
SMARCB1SWI/SNFepithelioid sarcomaimmune checkpoint inhibitorimmunotherapyrhabdoid tumor

More Related Videos

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.2K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

743

Related Experiment Videos

Last Updated: Sep 29, 2025

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.5K
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.2K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

743

Area of Science:

  • Oncology
  • Immunology
  • Cancer Genetics

Background:

  • Mutations in the SWItch Sucrose Non-Fermentable (SWI/SNF) complex are found in 20% of human cancers.
  • SMARCB1 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily B, member 1) is the most frequently mutated core subunit.
  • SMARCB1 loss is a key driver in malignancies like malignant rhabdoid tumors (MRT) and renal medullary carcinoma (RMC).

Purpose of the Study:

  • To review preclinical and clinical evidence supporting immunotherapy for SMARCB1-deficient tumors.
  • To discuss the potential of immune checkpoint inhibitors as a therapeutic strategy.
  • To highlight challenges in developing personalized immunotherapy for these cancers.

Main Methods:

  • Review of existing preclinical research.
  • Analysis of clinical trial data.
  • Discussion of molecular profiling techniques.

Main Results:

  • SMARCB1-deficient pediatric MRT and RMC exhibit immunogenicity despite low mutational burden.
  • Some SMARCB1-deficient diseases have shown positive responses to immune checkpoint inhibitors.
  • Heterogeneity exists across SMARCB1-loss driven malignancies.

Conclusions:

  • Immunotherapy, particularly immune checkpoint inhibitors, shows promise for treating SMARCB1-defective tumors.
  • Personalized immunotherapy approaches are needed, considering tumor and microenvironment molecular profiles.
  • Further research is warranted to overcome challenges in developing tailored treatments.